After Niagara the company faces three pivotal catalysts; none is a slam-dunk.

A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.

Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.

Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.

The company sticks with EZH2, despite others adding EZH1 inhibition.

Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.

Meanwhile, the RayzeBio-originated RYZ101 is back in Action.

ASP3082 grabs some early attention among degraders set to feature at ESMO.

Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.